ORCL · News · 20261020N

AstraZeneca AI Healthcare Partnership

ORACLE CORP · 2026-10-20 · Importance 31 · Surprise 42 · In source text

Oracle and AstraZeneca entered a nonbinding agreement on October 20, 2026, to use Oracle’s real-world data, cloud, AI, analytics, and clinical workflow capabilities with AstraZeneca’s scientific and therapeutic expertise. The collaboration will explore earlier identification of eligible clinical-trial patients, faster evidence generation, and integration of research findings into routine care workflows. Initial focus areas include oncology, cardiovascular, renal and metabolic diseases, respiratory and immunology conditions, and rare diseases. The companies plan to operate across the United States, Middle East, and Europe under applicable regulatory frameworks and shared governance arrangements.

Key facts

• Oracle announced an agreement with AstraZeneca on Oct. 20, 2026 to explore how AI and real-world data can help clinicians identify eligible patients for clinical trials, accelerate evidence generation, and bring research insights into care. source
• The collaboration is expected to combine AstraZeneca's scientific and therapeutic expertise with Oracle's health data, cloud, AI, analytics, and clinical workflow capabilities. source
• Oracle and AstraZeneca said the initiative will target disease areas including oncology, cardiovascular, renal, metabolic, respiratory, immunology, and rare diseases. source
• Seeking Alpha reported the partnership will advance across multiple regions, including the U.S., the Middle East, and Europe, in compliance with applicable regulatory frameworks. source

Impact estimates